ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

DXR Daxor Corporation

9,5527
0,00 (0,00%)
13 Mai 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Daxor Corporation DXR NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 9,5527 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
9,5527
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
16.4.202414:00GLOBENew Studies Prove the Clinical Benefits of Daxor’s Blood..
15.4.202414:00GLOBEDAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR..
10.4.202414:00GLOBEDaxor Corporation Announces New Hospital Account at Leading..
01.4.202414:00GLOBEDaxor Corporation to Exhibit at the American College of..
25.3.202413:00GLOBEDaxor Corporation Acquires Volumex® and Megatope® From Its..
22.3.202413:00GLOBEDaxor Corporation to Hold Investor Call Discussing Fiscal..
18.3.202419:18GLOBEDaxor Corporation CEO and President Michael Feldschuh..
11.3.202413:00GLOBEDaxor Announces Sales to Three New Hospitals Furthering..
08.3.202419:49EDGAR2Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of..
08.3.202414:00GLOBEMulti-Center Study Presented by Duke at Heart Failure..
06.3.202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202423:28EDGAR2Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of..
29.2.202422:15EDGAR2Form NT-NCSR - Notice under Exchange Act Rule 12b-25 of..
26.2.202414:00GLOBEDaxor Corporation to Exhibit at the Technology and Heart..
12.2.202414:00GLOBEDaxor Corporation Starts 2024 with Ongoing Growth in New..
07.2.202414:00GLOBEDaxor Corporation Closes Q4 2023 with Growth in New Sales to..
29.1.202414:00GLOBEDaxor Corporation to Exhibit at the Society of Nuclear..
16.1.202414:00GLOBEDaxor Corporation to Exhibit at the Society for Critical..
09.1.202414:00GLOBEDAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME..
02.1.202414:52EDGAR2Form 8-K - Current report
02.1.202414:30GLOBEDaxor Corporation Submits Dual 510(k)/CLIA-waiver..
06.12.202321:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.12.202303:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.12.202302:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.11.202312:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24.11.202319:53EDGAR2Form NPORT-P - Monthly Portfolio Investments Report on Form..
24.11.202317:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.11.202314:00GLOBENew Randomized Controlled Trial Demonstrates the Efficacy of..
13.11.202312:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09.11.202314:00GLOBEDaxor Corporation Awarded New Patent for Remote Monitoring..
02.11.202323:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.10.202323:27EDGAR2Form 8-K - Current report
16.10.202318:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.10.202314:00GLOBEExpert Panelists Advocate Use of Daxor’s Technology to..
11.10.202314:00GLOBENew Data from Banner University Medicine Demonstrating..
04.10.202314:00GLOBEDaxor Corporation Awarded Support from the National..
27.9.202314:00GLOBEDaxor Corporation to Exhibit at the Heart Failure Society of..
26.9.202315:14EDGAR2Form 40-17G - Fidelity Bond [Rule 17G-1(g)]
26.9.202314:00GLOBEDAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR..
20.9.202322:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11.9.202318:00GLOBEDaxor Corporation Awarded $305K Grant from the National..
07.9.202315:15GLOBEDaxor Corporation to Present at the H.C. Wainwright 25th..
28.8.202322:15GLOBEDaxor Corporation CEO and President Michael Feldschuh..
28.8.202322:05GLOBEDaxor Corporation Reports a 20.64 Percent Increase in..
28.8.202322:01EDGAR2Form N-CSRS - Certified Shareholder Report, Semi-Annual
15.8.202313:14EDGAR2Form N-PX - Annual Report of proxy voting record of..
10.8.202314:00GLOBEJACC-HF Reports Successful Heart Failure Trial With Daxor..
13.7.202322:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.7.202322:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13.7.202322:48EDGAR2Form 4 - Statement of changes in beneficial ownership of..

Kürzlich von Ihnen besucht